# Jin Medical International Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Jin Medical International Ltd.). ## Overview Jin Medical International Ltd. designs, manufactures and sells rehabilitation medical equipment, centered on wheelchairs and living aids for people with disabilities, older adults, and rehabilitation users. The company is headquartered in Changzhou, Jiangsu Province, China and operates manufacturing facilities in China while distributing products domestically and through overseas distributors. ## Products & services • Manual and rehab wheelchairs • Lightweight wheelchair models • Ergonomic wheelchair variants • Living aids for daily mobility • Rehabilitation medical equipment - **Wheelchairs** (75%) — Manual and rehabilitation wheelchairs sold through domestic and international distributors. - **Living aids** (25%) — Daily living and mobility support products for disabled and elderly users. - Manual and rehab wheelchairs - Lightweight wheelchair models - Ergonomic wheelchair variants - Living aids for daily mobility - Rehabilitation medical equipment ## Customers The company sells primarily to distributors that supply rehabilitation and mobility products in China and export markets, especially Japan. End users include people with disabilities, elderly individuals, and patients needing rehabilitation support, but the company’s commercial customers are mainly distributors rather than direct consumers. Its product mix and model count suggest demand from institutional resellers that need a broad catalog for mobility and care applications. - **China distributors** (primary) — Buy wheelchairs and living aids for domestic resale across rehabilitation and elder-care channels. - **Japan distributors** (primary) — Buy the majority of wheelchair models for resale in Japan's mobility aid market. - **International distributors** (secondary) — Buy selected products for resale in overseas rehabilitation and mobility markets. - **End users and patients** (secondary) — Use the products for mobility assistance, disability support, and rehabilitation. - Distributors in China that resell mobility equipment - Distributors in Japan for wheelchair and rehab products - International distributors serving local healthcare channels - End users needing mobility and rehabilitation support - Purchasing driven by product range, comfort, and lightweight design ## Geography Jin Medical is based in Changzhou, China and manufactures in Jiangsu and Anhui provinces. The business is concentrated in China and Japan, with additional sales through more than 20 international distributors; the company also notes that the majority of wheelchair products are sold to distributors in Japan and China. - **China** (50%) — Core manufacturing base and major distribution market - **Japan** (35%) — Major destination for wheelchair sales - **International other** (15%) — Other export markets served through distributors - Headquartered in Changzhou, Jiangsu Province, China - Manufacturing plants in Changzhou and Taizhou, Jiangsu - New facility under development in Chuzhou, Anhui - Core sales channels in China and Japan - Additional international distributor network beyond Asia ## Strategy The company is focused on broadening its rehabilitation product portfolio, maintaining lightweight and ergonomic design capability, and expanding manufacturing capacity in China. It also emphasizes supply chain diversification, regional manufacturing flexibility, and compliance across markets to support overseas distribution and manage geopolitical exposure. - **Product innovation in wheelchairs** (medium-term) — A broader and better-designed product line supports distributor demand and helps defend share in mobility equipment. - **Manufacturing expansion** (medium-term) — Additional capacity supports growth, operational flexibility, and supply reliability for domestic and export orders. - **Distribution network development** (short-term) — The business relies on distributors to reach end markets efficiently in China and overseas. - **Geopolitical and supply chain resilience** (short-term) — Cross-border sourcing and sales create exposure to policy and logistics disruptions. - Expand wheelchair and living aids product range - Increase manufacturing capacity in China - Differentiate with lightweight, ergonomic designs - Strengthen distributor relationships in Japan and China - Diversify supply chain and manufacturing footprint ## Risks Jin Medical depends heavily on distributor channels and on demand for rehabilitation and mobility products in China, Japan, and export markets, so channel concentration or end-market softness could affect sales. The company also faces manufacturing, regulatory, and geopolitical risks typical of cross-border industrial producers, including U.S.-China policy shifts, supply chain interruptions, and compliance requirements in multiple markets. - **Distributor concentration** [high] — The company sells mainly through distributors, with major exposure to China and Japan channels. - **Geopolitical and trade risk** [high] — Management explicitly notes U.S.-China relations and the need for supply chain diversification. - **Manufacturing execution risk** [medium] — New facilities and multi-plant operations require scale-up discipline and consistent quality control. - **Regulatory compliance risk** [medium] — Medical mobility products require compliance across different markets and standards. - **Foreign exchange volatility** [medium] — The company reports foreign currency translation gains and losses, indicating FX sensitivity. - Distributor concentration can pressure volumes if channel demand weakens - Geopolitical tension may disrupt exports, sourcing, or compliance - Manufacturing execution risk as capacity expands in China - Regulatory changes can affect product approvals and market access - Currency and foreign exchange swings can affect translated results ## Accounting The company reports one operating and reportable segment, so consolidated expenses and performance metrics drive most of the financial statements. Investors should watch revenue recognition by product type and geography, foreign currency translation effects from overseas operations, and estimates tied to working capital, taxes, and the build-out of new facilities. - **Single operating segment** — Reduces external visibility into product or regional profitability - **Revenue disaggregation** — Important for understanding mix and regional dependence - **Foreign currency translation** — Can materially affect equity and total comprehensive income - **Capital expenditures and long-lived assets** — Affects depreciation and balance sheet asset values - Single operating segment means limited segment-level transparency - Revenue disaggregation by product type and geography matters - Foreign currency translation affects comprehensive income - New facility build-out may create capitalized asset estimates - Loan and related-party borrowing terms affect liquidity disclosure --- *Last updated: 2026-09-28T12:04:10.731965+00:00*